Reflections from JPM 2025: A CEO’s Perspective on Biopharma’s New Era Having just returned from the 2025 JP Morgan Healthcare Conference, I am energized by the transformative developments shaping the biopharma industry. With over 8,000 professionals in attendance and more than 500 companies presenting, the conference underscored the resilience, creativity, and forward-thinking mindset driving the sector today. The themes of this year’s conference — strategic M&A, Read more
Serbia is a Rising Star in Clinical Research In recent years, regulatory timelines for clinical trials in Serbia have grown longer, posing challenges for some biopharma companies. However, recent trends indicate a significant reduction in these timelines, fostering optimism for sponsors and stakeholders. This positive shift underscores Serbia’s commitment to creating a conducive environment for clinical research. A Legacy of Innovation For centuries, Read more
Clinical Research Focus. 36th Edition Reflections on ASH 2024: Transformative Breakthroughs in Hematology-Oncology The 66th American Society of Hematology (ASH) Annual Meeting, held from December 7-10 in San Diego and online, delivered on its promise of showcasing groundbreaking advancements in hematology and oncology. Cromos Pharma’s CEO Vlad Bogin attended this event and prepared his takeaways on the most exciting and Read more
The Most Impactful FDA Drug Approvals of 2024: A Transformative Year for Biopharma As we approach the end of 2024, the biopharmaceutical industry has seen a wave of innovation, marked by FDA approvals that promise to reshape treatment paradigms across various therapeutic areas. From breakthrough therapies for genetic disorders to novel approaches in oncology and chronic diseases, 2024 has been a pivotal year. Here’s a comprehensive look at Read more
